IntraBio Receives Regulatory Authorization to Begin Pivotal Phase III Trial of Levacetylleucine in CACNA1A-Related Disorders Across Participating Regions

Key Takeaways

• Phase III trial for levacetylleucine cleared in US, UK, EU, Switzerland.
• Twelve multinational sites will start recruiting patients immediately.
• CACNA1A disorders affect ~1 in 11,700, with no approved therapies.
• Trial uses 12‑week double‑blind crossover design proven in NPC and A‑T.
• Success could expand IntraBio’s rare‑neurology portfolio and boost revenue.

Pulse Analysis

IntraBio Inc., a Texas‑based biopharma focused on rare neurological conditions, has secured simultaneous regulatory clearance for its pivotal Phase III trial of levacetylleucine in CACNA1A‑related disorders across the U.S., U.K., EU and Switzerland. This multi‑regional approval streamlines enrollment and positions the company to generate robust data under a unified protocol. Leveraging the same crossover design that earned FDA and EMA approval for AQNEURSA in Niemann‑Pick disease type C, IntraBio demonstrates confidence in its platform’s reproducibility and regulatory strategy. The clearance also aligns with IntraBio’s strategy to synchronize global development, reducing timelines and operational redundancies.

CACNA1A‑related disorders, caused by mutations in the calcium‑channel gene CACNA1A, affect roughly one in 11,700 individuals and manifest as episodic ataxia, seizures, migraine and progressive motor decline. Until now, patients have faced a therapeutic vacuum, with no disease‑specific clinical trials or approved drugs. The IB1001‑304 study will enroll participants at twelve sites, employing a 12‑week double‑blind, placebo‑controlled crossover format that allows each patient to serve as their own control, enhancing statistical power in a rare‑disease setting. Baseline assessments will capture motor function, eye movement and quality‑of‑life metrics, providing a comprehensive efficacy readout.

If the trial confirms safety and efficacy, IntraBio could launch its first therapy for CACNA1A‑related disorders, expanding a portfolio already anchored by AQNEURSA and a pending sNDA for Ataxia‑Telangiectasia. The market for rare‑neurology treatments is growing, with premium pricing and orphan‑drug incentives driving attractive returns. Successful data would not only address a critical unmet need but also reinforce investor confidence, potentially boosting the company’s valuation and funding pipeline expansion into other calcium‑channel pathologies. Analysts project that an approved CACNA1A therapy could generate $150 million in annual sales, given the orphan‑drug premium and global prevalence.